Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.

In addition to the authors, the POWER 1 study group included the following investigators and contributors to the design, conduct and analysis of the study. Australia: D. Cooper, J. Hoy, P. Martinez and C. Workman; Austria: A. Rieger; Belgium: N. Clumeck, C-M. Farber and F. van Wanzeele; Brazil: C.A. Da Cunha, R. Pedro, F. de Queiroz Telles, A. Timerman and J. Valdez-Madruga; Canada: P. Junod, D. Kilby, J. McLeod, R. O’Brien, A. Rachlis, C Tsoukas and S. Walmsely; France: J-F. Delfraissy, P-M. Girard, A. Lafeuillade, J-M. Molina, F. Raffi, J. Reynes, W. Rozenbaum and D. Vittecoq; Germany: K. Arasteh, H. Carls, S. Esser, H. Jaeger, J-A. Rump, C. K. Schewe, D. Schuster, S. Staszewski and A. Woehrmann; Hungary: D. Ba´nhegyi; Italy: A. Lazzarin, F. Mazzotta and V. Vullo; Poland: A. Boron-Kaczmarska; Portugal: T. Branco, R. Sarmento-e-Castro and J. Vera; Spain: K. Auirrebengoa, B. Clotet, J. Gonzalez-Lahoz, J. Iribarren, H. Knobel, M. J. Perez-Elias, J. J. Picazo and I. Santos; Switzerland: E. Bernasconi and M. Opravil; UK: C. Leen and E.Wilkins.